A Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19

Status:
Completed

Trial end date:
2020-08-03

Target enrollment:

Participant gender:

The objective: to study the efficacy and safety of levilimab in subjects with severe COVID-19.

Phase 3

Biocad